Specific insulin/IGF1 hybrid receptor activation assay reveals IGF1 as a more potent ligand than insulin
Crossref DOI link: https://doi.org/10.1038/srep07911
Published Online: 2015-01-21
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Slaaby, Rita
Text and Data Mining valid from 2015-01-21
Version of Record valid from 2015-01-21
Article History
Received: 4 September 2014
Accepted: 19 December 2014
First Online: 21 January 2015
Competing interests
: Dr Slaaby is an employee at Novo Nordisk and owns stocks/shares in the company.